163 related articles for article (PubMed ID: 19940550)
41. Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data.
McDermott DF; George DJ
Cancer Treat Rev; 2010 May; 36(3):216-23. PubMed ID: 20116176
[TBL] [Abstract][Full Text] [Related]
42. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
Gollob JA
Clin Genitourin Cancer; 2005 Dec; 4(3):167-74. PubMed ID: 16425993
[TBL] [Abstract][Full Text] [Related]
43. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
44. Nox4 is critical for hypoxia-inducible factor 2-alpha transcriptional activity in von Hippel-Lindau-deficient renal cell carcinoma.
Maranchie JK; Zhan Y
Cancer Res; 2005 Oct; 65(20):9190-3. PubMed ID: 16230378
[TBL] [Abstract][Full Text] [Related]
45. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
Siemeister G; Weindel K; Mohrs K; Barleon B; Martiny-Baron G; Marmé D
Cancer Res; 1996 May; 56(10):2299-301. PubMed ID: 8625303
[TBL] [Abstract][Full Text] [Related]
46. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma.
Kaelin WG
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):680s-684s. PubMed ID: 17255293
[TBL] [Abstract][Full Text] [Related]
47. (1)H NMR metabolomics analysis of renal cell carcinoma cells: Effect of VHL inactivation on metabolism.
Cuperlovic-Culf M; Cormier K; Touaibia M; Reyjal J; Robichaud S; Belbraouet M; Turcotte S
Int J Cancer; 2016 May; 138(10):2439-49. PubMed ID: 26620126
[TBL] [Abstract][Full Text] [Related]
48. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.
Smith K; Gunaratnam L; Morley M; Franovic A; Mekhail K; Lee S
Cancer Res; 2005 Jun; 65(12):5221-30. PubMed ID: 15958567
[TBL] [Abstract][Full Text] [Related]
49. Action of hypoxia-inducible factor in liver and kidney from mice with Pax8-rtTA-based deletion of von Hippel-Lindau protein.
Mathia S; Paliege A; Koesters R; Peters H; Neumayer HH; Bachmann S; Rosenberger C
Acta Physiol (Oxf); 2013 Mar; 207(3):565-76. PubMed ID: 23384425
[TBL] [Abstract][Full Text] [Related]
50. Sunitinib malate for the treatment of renal cell carcinoma.
Wood L
Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
[TBL] [Abstract][Full Text] [Related]
51. Angiogenesis and angiogenic inhibitors in renal cell carcinoma.
Sawhney R; Kabbinavar F
Curr Urol Rep; 2008 Jan; 9(1):26-33. PubMed ID: 18366971
[TBL] [Abstract][Full Text] [Related]
52. Novel treatment strategies in clear-cell metastatic renal cell carcinoma.
van Spronsen DJ; de Weijer KJ; Mulders PF; De Mulder PH
Anticancer Drugs; 2005 Aug; 16(7):709-17. PubMed ID: 16027518
[TBL] [Abstract][Full Text] [Related]
53. Progress of molecular targeted therapies for advanced renal cell carcinoma.
Conti A; Santoni M; Amantini C; Burattini L; Berardi R; Santoni G; Cascinu S; Muzzonigro G
Biomed Res Int; 2013; 2013():419176. PubMed ID: 24093097
[TBL] [Abstract][Full Text] [Related]
54. Emerging oral VEGF inhibitors for the treatment of renal cell carcinoma.
Stitzlein L; Rao P; Dudley R
Expert Opin Investig Drugs; 2019 Feb; 28(2):121-130. PubMed ID: 30572736
[TBL] [Abstract][Full Text] [Related]
55. Prognostic and predictive biomarkers in renal cell carcinoma.
Vickers MM; Heng DY
Target Oncol; 2010 Jun; 5(2):85-94. PubMed ID: 20582732
[TBL] [Abstract][Full Text] [Related]
56. Anti-angiogenic therapy in renal cell carcinoma.
Sharma SG; Nanda S; Longo S
Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):77-83. PubMed ID: 19601920
[TBL] [Abstract][Full Text] [Related]
57. Targeted therapy in renal cell carcinoma.
Favaro JP; George DJ
Expert Opin Investig Drugs; 2005 Oct; 14(10):1251-8. PubMed ID: 16185167
[TBL] [Abstract][Full Text] [Related]
58. Molecular Targets and Angiogenesis in Renal Cell Carcinoma, A Multitarget Approach: Mini Review.
Badal SAM; Aiken WD; Chin SN
Curr Drug Targets; 2017; 18(10):1204-1213. PubMed ID: 27138755
[TBL] [Abstract][Full Text] [Related]
59. A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.
Suwaki N; Vanhecke E; Atkins KM; Graf M; Swabey K; Huang P; Schraml P; Moch H; Cassidy AM; Brewer D; Al-Lazikani B; Workman P; De-Bono J; Kaye SB; Larkin J; Gore ME; Sawyers CL; Nelson P; Beer TM; Geng H; Gao L; Qian DZ; Alumkal JJ; Thomas G; Thomas GV
Sci Transl Med; 2011 Jun; 3(85):85ra47. PubMed ID: 21632985
[TBL] [Abstract][Full Text] [Related]
60. Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment.
Garje R; An JJ; Sanchez K; Greco A; Stolwijk J; Devor E; Rustum Y; Zakharia Y
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]